Hologic made its third big acquisition of 2021 and Agilent agreed to pay up to $695m for Resolution Bioscience to extend its precision oncology capabilities.

Japanese firm joins increasing global interest in PROTAC approach to cancer as it links with UK university for drug discovery collaboration.

Japanese pharma firm’s new venture capital fund aims to support and gain access to external innovation both at home and in the US, while a new alliance with a Japanese tech services firm will pursue opportunities in digital health and dementia.

America Invents Act did not alter the meaning of "on sale," unanimous court finds, so a confidential sale can qualify as prior art.